intoplicine has been researched along with Leukemia P388 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lavelle, F; Poddevin, B; Pommier, Y; Riou, JF | 1 |
| Barret, JM; Etiévant, C; Guminski, Y; Hill, BT; Kruczynski, A; Perrin, D; van Hille, B | 1 |
2 other study(ies) available for intoplicine and Leukemia P388
| Article | Year |
|---|---|
Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials.
Topics: Animals; Antineoplastic Agents; DNA Damage; DNA, Neoplasm; Humans; Indoles; KB Cells; Kinetics; Leukemia P388; Mice; Pyridines; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1993 |
F 11782, a dual inhibitor of topoisomerases I and II with an original mechanism of action in vitro, and markedly superior in vivo antitumour activity, relative to three other dual topoisomerase inhibitors, intoplicin, aclarubicin and TAS-103.
Topics: Aclarubicin; Aminoquinolines; Animals; Antineoplastic Agents; Cell Division; Enzyme Inhibitors; Etoposide; Humans; Indenes; Indoles; Leukemia L1210; Leukemia P388; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Naphthalenes; Pyrans; Pyridines; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2000 |